We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GSABC Signs Long-Term Supply Agreement with Chiron
News

GSABC Signs Long-Term Supply Agreement with Chiron

GSABC Signs Long-Term Supply Agreement with Chiron
News

GSABC Signs Long-Term Supply Agreement with Chiron

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GSABC Signs Long-Term Supply Agreement with Chiron "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Group Services for America's Blood Centers (GSABC), has announced that it had signed a multi-year agreement with Chiron, a business unit of Novartis Vaccines and Diagnostics, for the purchase of the PROCLEIX® West Nile Virus Assay and the PROCLEIX® HIV- 1/HCV Assay.

The agreement extends the existing supply contract with Chiron, providing members of America's Blood Centers continued access to assays that have intercepted thousands of infected blood samples since their approval by the FDA.

"We are very pleased to have reached this new agreement with Chiron," said Jerry Haarmann, president of the newly formed group purchasing organization.

"Ensuring a safe and reliable blood supply is a critical priority for us. This new agreement means that our members will continue to provide more than 4,200 hospitals and healthcare facilities across North America with blood products screened with the most sensitive technology currently available on the market."

The PROCLEIX nucleic acid tests incorporate nucleic acid testing (NAT) technology to detect viral RNA and DNA in donated blood and plasma during the very early stages of infection, when those infectious agents are present but cannot be detected by immunodiagnostic tests.

Advertisement